Bifogade filer
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | Nordic SME Sweden |
Sektor | Hälsovård |
Industri | Medicinteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
Prolight Diagnostics AB (publ) (“Prolight” or the “Company”) hereby announces the final outcome of the rights issue of shares, which the board of directors resolved on May 21, 2025, and later approved by an Extraordinary General Meeting on June 10, 2025 (the “Rights Issue”). The Rights Issue was fully subscribed whereas approximately 70.2 percent was subscribed with subscription rights and approximately 29.8 percent was subscribed without subscription rights. Through the Rights Issue, the Company will receive net proceeds of approximately SEK 100.3 million before issue costs and set-offs.
CEO Ulf Bladin comment on the outcome
”We would like to extend our sincere thanks to our shareholders for the strong support you have shown, and warmly welcome our new investors. Your commitment has enabled a cost-effective financing without the need for underwriters. The significant participation from our board, management, and employees, who together invested approx. SEK 10 million, as well as our instrument contract manufacturing partner, ITL, contributing approx. SEK 9.9 million, underscores the shared confidence in our strategy and future. The capital raised through this rights issue enables us to optimize, verify, and complete the development of our point-of-care system Psyros, finalize validated pilot production lines for both cartridges and instruments, accelerate business development efforts aimed at securing a commercial partnership and prepare for market access, initiate the clinical performance study and regulatory processes, as well as to build inventory ahead of commercial launch of Psyros in Europe”, said Ulf Bladin, CEO at Prolight Diagnostics.
Preliminary outcome of the Rights Issue
The subscription period in the Rights Issue ended on June 30, 2025. The final outcome shows that 351 805 515 shares, corresponding to approximately 70.2 percent of the Rights Issue, have been subscribed for with subscription rights in the Rights Issue. In addition, applications have been received to subscribe for 149 686 965 shares without subscription rights, corresponding to approximately 29.8 percent of the Rights Issue. Thus, the final outcome shows that a total of 501,492,480 shares has been subscribed for in the Rights Issue, with and without subscription rights, corresponding to a subscription rate of 100 percent. The Rights Issue is thus fully subscribed.
Allocation of shares subscribed without subscription rights
Allotment of shares subscribed for without subscription rights has been made in accordance with the principles set out in the information document published by the Company on June 13, 2025, in connection with the Rights Issue. Notice of such allotment will be announced separately through a settlement note. Nominee-registered shareholders will receive notification of allotment in accordance with instructions from the respective nominee.
Trading in paid subscribed shares (“BTA”)
The last day of trading in BTAs is expected to be July 16, 2025. Trading in the new shares subscribed for with and without subscription rights is expected to commence on Nordic SME Sweden on or around July 18, 2025.
Shares and share capital
Through the Rights Issue, the total number of shares in the Company will increase by 501,492,480 shares, from 702,089,478 shares to 1,203,581,958 shares, and the share capital will increase by SEK 50,149,248.00, from SEK 70,208,947.80 to SEK 120,358,195.80. This corresponds to a dilution effect of approximately 41.7 percent of the total number of shares and votes in the Company.
Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.